Why the study?
Does the presence of a BP-elevation response during radiofrequency energy delivery predict greater blood pressure reduction following renal artery sympathetic denervation in patients with drug-resistant hypertension?
Does the presence of a BP-elevation response during radiofrequency energy delivery predict greater blood pressure reduction following renal artery sympathetic denervation in patients with drug-resistant hypertension?
A BP-elevation response during radiofrequency renal denervation serves as an effective intraprocedural marker predicting greater long-term blood pressure reduction.
Answers are grounded in this paper and cite their sources.
BP response during renal denervation may aid responder identification; leaves open its role in selection or trial design pending prospective data.
BACKGROUND: Previous studies showed that radiofrequency energy delivery of the renal artery could induce an immediate and substantial blood pressure (BP)-elevation response, which might be indicative of the increase in central sympathetic nervous activity. OBJECTIVE: The current study was to investigate whether the presence of BP-elevation response to radiofrequency energy delivery can serve as a surrogate to predict BP reduction following renal artery sympathetic denervation (RDN). METHOD: Data were collected on 67 patients undergoing RDN for drug-resistant hypertension. The BP-elevation response to radiofrequency application was defined as elevation of SBP by at least 10 mmHg during radiofrequency energy delivery. The extent of BP reduction at 1, 3, 6, 12 months after RDN were analyzed. Multivariable linear regression analysis of baseline and procedural characteristics was performed to identify the determinants of BP reduction after RDN. RESULTS: Ten patients (14.9%) were classified as nonresponders to radiofrequency delivery and showed significantly lower BP reduction compared with responders. The SBP reductions of radiofrequency delivery responders vs. nonresponders were 31.2 ± 8.6 vs. 11.4 ± 8.6 mmHg, 36.3 ± 10.0 vs. 14.6 ± 10.6 mmHg, 39.9 ± 9.9 vs. 15.2 ± 8.8 mmHg, and 40.0 ± 8.7/13.5 ± 5.8 mmHg (P < 0.001 for all) at 1, 3, 6, and 12 months, respectively. On multiple linear regression analysis, higher baseline office SBP, the presence of BP-elevation response to radiofrequency energy delivery, and especially larger number of BP-elevation response points, were independent predictors of SBP reduction at 6-month and 12-month follow-up. CONCLUSION: Baseline SBP and BP-elevation response during radiofrequency ablation, as well as larger positive response points to radiofrequency energy delivery could be an effective intraprocedural predictive markers to long-term procedural success of RDN.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: